My Rx Pad Email this list with product links
No Data Available
A curated map of 70 leading digital health investors across the U.S. and Europe — by stage, strategy, and fit. From seed specialists and Series A leads to crossover funds, strategic CVCs, and healthcare PE.
Capital is still active, but it has become more selective, more evidence-driven, and more tied to distribution, workflow integration, and measurable ROI. Per Galen Growth, digital health raised approximately $164B across 10,100+ deals globally since 2021, with 2025 on track to reach an estimated $28B in annual capital. U.S. digital health funding hit $17.2B in 2024, a 4% year-over-year increase — breaking a two-year decline. Mega-rounds and unicorn velocity have moderated from the 2021 peak, but the market is more selective rather than closed. AI-native digital health, ambient documentation, and value-based care infrastructure remain the most active themes.
Use this map as a starting point, not a target list. The investors below are organized by stage, with a Best fit tag on each card indicating the company profile that firm typically backs. Type tags distinguish generalists, health-specialists, strategic CVCs, and crossover/PE. The best investor for your company depends on stage, evidence base, target buyer, regulatory pathway, and distribution needs — verify current thesis and check size before outreach.
The investors who write the first check — pre-seed, seed, and late-seed specialists who back digital health founders before product-market fit. Heavy U.S. concentration, with European specialists for cross-Atlantic founders.
The original dedicated digital health venture fund (founded 2010). Invests pre-seed through Series A in software- and data-driven health companies. Sister firm Rock Health Advisory advises Fortune 500 clients on digital health strategy. Notable portfolio: Omada Health, Collective Health, 100+ companies.
Chicago-based seed-to-Series A digital health investor empowering informed, connected health consumers. Notable for backing Transcarent (unicorn), Livongo (acquired by Teladoc), Higi, HomeThrive. ~42 portfolio companies. Founders Glen Tullman, Lee Shapiro bring operator depth.
Boston-based healthcare technology specialist with $350M latest fund. Series A–C focus, $5M–$30M checks. One of the most active U.S. digital health investors in 2024 (16 deals). Notable: Bright Health, HealthVerity, Aetion, HealthifyMe, Oshi Health.
Seed-stage digital health specialist focused on care delivery innovation and digital health infrastructure. Notable: Marley Medical, Turquoise Health. Operates with deep clinical and operator network. $500K–$2M initial checks.
Seed-stage firm investing in healthcare software and AI-driven services solving operational and clinical bottlenecks. Team includes investors, operators, and former policymakers. Portfolio: Brellium, Claim Health, UrgentIQ, ArcHouse, Cybexys.
NYC-based fund (founded 2019) focused on vertical specialty care, digital therapeutics, and healthcare IT. Founder Adam Besvinick brings nearly a decade of digital health investing. Avoids hardware, biotech, and life sciences. Notable: Hone Health, Sylvan Health.
Pre-seed and seed fund bringing frontline clinical insight to digital health, health IT, tech-enabled services, and Class I/II medical devices. $100K–$300K checks. Built by clinicians for clinician-founders. Notable: Posterity Health, Conceivable Life Sciences.
Austin-based pre-seed and seed venture firm exclusively partnering with healthcare founders in the first 12–24 months. Focuses on the “business of care” (data, dollars, delivery). Avoids biotech, devices, and therapeutics. Founded 2021.
Barcelona-based seed-stage VC exclusively dedicated to healthtech. Invests in early-stage companies across Europe and globally. €100K–€1M typical investments. Bridges European healthcare innovators with international markets.
Germany’s leading early-stage tech investor. Backs deep-tech, digital health, and AI startups from pre-seed to seed. Initial €800K+ with follow-on up to €30M. Public-private fund-of-funds with co-investment network.
London-based early-stage venture firm backing global-market startups in healthtech, AI/ML, fintech, and software. One of Europe’s most prolific seed funds with thousands of portfolio companies. Founded 2007.
Zurich-based digital health and health IT seed/Series A specialist. Pan-European focus on regulated healthtech, AI, and clinical-grade infrastructure. Operator-led with deep DACH-region network.
Early-stage venture fund (founded 2021) seeding the next generation of digital health, healthtech, and longevity startups focused on extending human healthspan. Seed and Series A focus on the democratization of medicine. Portfolio: Sanctuary AI, Biotia, Immunis, BeeKeeper AI, CardiaTec. Co-founded by Ricky Mehra and Daniel Kraft, MD.
Seattle-based healthcare technology investor focused on digital health, devices, oral health, healthcare SaaS, consumerization, and wellness. Seed-stage specialist with active platform-supporting model. Focus on category-defining commercial-stage health-tech.
European pan-European pre-seed and seed firm with active healthtech vertical. Multi-stage capability with a sector-specialist team for digital health and life sciences. €100K–€1M initial checks. One of the most active early-stage VCs in Europe.
Series A is where digital health goes from product to traction. These firms led 2024’s most active deal flow — backing the founders who’ve crossed product-market fit and are scaling enterprise contracts, payer relationships, or consumer adoption.
a16z’s dedicated $1.5B+ healthcare fund. Most active digital health investor in 2024 (26 deals). Spans seed to growth, $1M–$100M+. Backs founders applying modern computer science to drug discovery and healthcare delivery. Partners include Vijay Pande, Julie Yoo, Jorge Conde.
Multi-stage VC with the Health Assurance Network leading the shift from sick care to proactive health. 30+ health-tech investments since 2021’s Health Assurance Fund launch. Notable: Devoted Health, Olive AI, Lyra Health, Transcarent.
Alphabet’s venture arm with a strong digital health practice. Seed through growth, with deep computational and ML expertise. A top Femtech investor. Notable: Flatiron Health, One Medical, Doctor on Demand.
AI-first healthcare investor with strong technical conviction. Among the most active early-stage digital health investors, with 11 deals in 2024. Notable: Rad AI, C the Signs. Tolerates technical risk; non-consensus bets.
50+ year history in healthcare and tech investing with deep healthcare IT, biotech, and tech-enabled services roots. Early and growth stages with focus on value-based care, digital health, and enterprise SaaS. Notable: Athenahealth, Devoted Health, Lyra Health, 10x Genomics.
Founded 1977. One of the largest global VC firms with dual tech/healthcare focus. Deploys across all stages with extensive regulatory networks for therapeutics and digital health platforms. Multi-billion fund cycles.
Storied Sand Hill Road firm investing in technology and health sectors at seed and Series A. Long history backing breakthrough health-tech companies. Notable health portfolio includes Ginger.io, Lyell Immunopharma.
Early-stage VC investing in healthcare and technology visionaries. Strong digital health portfolio focused on access to care and patient outcomes. Co-led major rounds in care delivery, behavioral health, and clinical AI.
Backs bold, frontier-tech companies pushing boundaries in healthcare, biotech, and deep science. Seed to growth stages with focus on AI, robotics, and next-gen therapeutics. Tolerates extreme technical risk.
NYC-based early-stage firm with deep operational support. Health-tech portfolio includes companies in care delivery, digital therapeutics, and patient infrastructure. Active operating team works alongside founders.
Deep-tech investor backing scientific and engineering breakthroughs. Healthcare portfolio focuses on computational biology, drug discovery, and clinical-grade AI. Seed to early venture rounds.
Pan-European multi-stage VC at the intersection of software and science. Backed digital health since 2006. Team of scientists, doctors, and operators. €500K–€5M initial checks with follow-on for scale.
San Francisco-based healthcare-focused investment firm spun out from Maverick Capital. Series A and growth-stage focus on healthcare AI, tech-enabled services, and scalable digital health platforms. Patient capital with a 10+ year horizon. Strong network of healthcare operators.
Israeli-American venture creation foundry building category-defining healthcare AI, data infrastructure, and cybersecurity-adjacent healthcare companies from inception. Co-founds and capitalizes companies in partnership with global health systems and corporate strategics. Active in U.S. and Israel.
UK/European early-stage VC backing healthtech, digital care, clinical decision support, AI drug discovery, and healthcare infrastructure. Series A focus with follow-on capacity. Strong network across NHS and European health systems for clinical validation.
Series B and C focus on growth-mode digital health companies with measurable enterprise traction, repeatable sales motion, and clear unit economics. Health-specialist VCs lead this segment, with a few generalist scale funds.
Healthcare and fintech specialist with deep care-delivery, payer-platform, and revenue-cycle expertise. Series B–growth, $5M–$100M+ checks. Notable: Athenahealth, VillageMD, Devoted Health, Cityblock Health.
Multi-stage investor with broad health-tech portfolio. Series A–growth focus on healthcare SaaS leaders, cloud-based platforms, and consumer health. Founded 1911. Notable: Hims, Sword Health, PillPack.
#1 ranked early-stage digital health investor per Galen Growth HT50 2025 (Investor Score 90.8%). Premier global software investor applying B2B SaaS scaling methodology to healthcare. Onsite scaling team supports portfolio post-investment.
Global VC arm of Fidelity Investments. Seed through growth in technology and healthcare. Focus on innovation and disruptive growth across digital health, biotech, medtech, and IT.
Healthcare venture platform with health system connections. Series A–B, $5M–$20M. Notable: Phreesia (IPO), IntelyCare, Olive. Strategic LP base of major U.S. health systems gives portfolio commercial validation.
Operator-led healthcare fund with deep payer/provider network. Series A–B, $5M–$25M. Focus on care delivery, behavioral health, and labor enablement for digital health platforms with enterprise traction.
Growth equity for scaling health-tech with proven traction. Series B+, $20M–$100M. Notable: DexCare. Targets post-pilot businesses with enterprise validation and growth-stage metrics.
Early-stage healthcare investor with concentrated, thematically coherent digital health portfolio. Focus on infrastructure, AI diagnostics, virtual specialty care, and women’s health. Operator-led.
Nashville-based healthcare-only VC. Founded by Bill Frist (former Senate Majority Leader, surgeon) and Bryan Cressey. Investments span tech-enabled services, behavioral health, value-based care, and digital health.
London-based VC founded by Niklas Zennström (Skype). Series A and onwards investments in European technology companies across digital health, AI, and consumer. Major European multi-stage scaling partner.
Trans-Atlantic VC investing in startups with global business potential. Founded 1996. Strong digital health and health AI portfolio with offices in London, San Francisco, and New York. Top-5 European digital health investor per Galen Growth.
Paris-based investment firm with significant venture and growth healthcare presence. A top-5 European digital health investor by deal activity. Multi-stage capital across digital health, life sciences, and software.
Healthcare-specialist VC focused on serving Medicare, Medicaid, and other underserved populations through value-based care and care delivery innovation. Founded by Andy Slavitt (former CMS Administrator), Trevor Price, and David Whitrap. Series A through growth. Notable: Cityblock Health, Strive Health.
Late-stage venture and growth equity for digital health companies on a path to IPO, strategic acquisition, or PE rollup. Crossover funds bridge the private-public gap, while traditional growth equity provides operational playbooks.
Global growth equity firm with major digital health and healthcare practice. A top-5 European digital health investor by deal activity. Notable: Doctolib, Ro, Modern Animal. Multi-stage but anchored at growth.
Crossover hedge fund and VC. Major late-stage investor in digital health unicorns during the 2020–22 boom (Cerebral, Ro, Capsule, Forward). Has become substantially more selective since 2022, with fewer but more concentrated late-stage digital health bets. Best-fit profile: pre-IPO companies with proven scaling metrics.
New York-based public-private crossover with technology and healthcare focus. Late-stage venture and growth equity. Notable digital health: Hims, Carbon Health, Ada Health, Komodo Health.
Public-markets investor with active venture-stage crossover practice in healthcare. Late-stage digital health and biotech. Provides bridge to public markets for pre-IPO companies.
Major public-markets crossover investor with significant late-stage digital health activity. Provides validation and IPO-pathway capital. Sister fund F-Prime Capital invests at venture stages.
World’s largest asset manager with active late-stage and crossover practice. Healthcare innovation team backs growth-stage digital health, biotech, and medtech. Provides scale capital and public-market continuity.
#1 ranked late-stage digital health investor per Galen Growth HT50 2025. Top investor for clinical-evidence-led ventures. Bridges private-late-stage and public markets for digital health and TechBio companies.
$100B+ mega-fund with healthcare and AI healthcare investing. A top late-stage digital health investor that has substantially moderated from 2020–22 peak; current strategy emphasizes selective, concentrated late-stage bets with emphasis on AI-native and platform companies. Notable: Cerebral, Pacific Biosciences, Roivant.
Global healthcare crossover with significant late-stage digital health and biotech activity. A top late-stage digital health investor. U.S., European, and Asian growth-stage investments.
San Francisco crossover specialist. Venture, growth, and crossover healthcare investing since 2007. Notable: BioNTech, Virta Health. Strong fit for healthcare companies on a public-markets trajectory.
NYC healthcare investor since 1994. Capital, information, and philanthropy across the healthcare spectrum. Seed through post-IPO. Notable: Nuvalent, Viatris. Highly active across digital health, devices, and therapeutics.
Bain Capital’s dedicated life sciences and healthcare arm. Growth equity and late-stage investing across biotech, medtech, healthcare services, and digital health. Strong partnership with operating companies.
Global multi-stage VC with dedicated healthcare practice spanning healthtech, digital health, medtech, biotech, and AI-enabled infrastructure. $7B+ AUM. Notable: Notable, Hippocratic AI, Atomwise. Strong cross-border capability connecting U.S. and Asia healthcare markets.
Healthcare-only growth equity firm investing in commercial-stage technology, services, and medtech companies. $20M–$80M check size. Notable digital health: Capital Rx, Mercato Partners health portfolio. Patient capital with operating support for scaling teams.
Strategic capital from health systems, payers, pharma, and tech platforms — plus dedicated healthcare PE growth funds. These investors bring distribution, deployment validation, and operational scale alongside capital.
#1 ranked growth-stage digital health investor per Galen Growth HT50 2025. CVS Health’s strategic VC arm reflecting an increasingly muscular role in care delivery, pharmacy, and benefits through digital tools.
UnitedHealth Group’s strategic venture arm. Seed to growth equity across value-based care, enterprise software, and enabling infrastructure. 70+ portfolio companies. Strategic LP relationship with Optum’s payer/provider/pharmacy ecosystem.
Strategic VC of Kaiser Permanente, the integrated care system. Backs digital health platforms aligned with Kaiser’s care model and values, with potential for system-wide deployment validation.
Cigna’s strategic venture investing arm. $250M committed capital. Focus on care delivery innovation, health analytics, and member engagement platforms aligned with Cigna’s integrated health services strategy.
Merck’s $500M+ digital health and tech-enabled health services fund. Multi-stage investments in companies that could create new business models for healthcare. Strong portfolio in clinical trials infrastructure, RPM, and patient engagement.
Multi-Blue strategic VC with capital commitments from multiple BCBS affiliates. Invests in payer-aligned digital health platforms across care management, member experience, and risk adjustment.
Strategic VC of Ascension. 13 health system LPs giving portfolio companies network of 100+ U.S. hospitals for go-to-market validation. Notable: Iodine, Verata, AristaMD.
EU-funded innovation network and investment vehicle. Backs European health-tech and digital health startups with both grant capital and venture investment. Cross-border deployment support and pan-European clinical validation pathways.
KKR’s dedicated healthcare growth equity strategy. Invests in scaled digital health, healthcare services, and tech-enabled providers. Provides PE-scale capital and operational playbooks for late-stage and pre-IPO companies.
Strategic healthcare venture firm jointly backed by Cambia Health Solutions and Mosaic Health (BCBS). Multi-stage investment from Series A through growth across payer/provider transformation, healthcare distribution, and scaling digital health platforms. Strong commercialization capability through plan-network.
Strategic VC of MemorialCare health system. Backs digital health, AI, and care delivery innovation aligned with health-system priorities. Provides clinical workflow piloting environment and deployment validation for portfolio companies seeking U.S. health system traction.
Healthcare VC firm spun out from Providence Health (renamed January 2025; previously Providence Ventures). $300M+ AUM, third fund. Mid- to late-stage venture investments in healthcare IT, MedTech, and tech-enabled services. Notable portfolio: Omada, DexCare, Kyruus, Xealth, Trilliant Health.
Mass General Brigham’s AI and Digital Innovation Fund. Companion to MGB Ventures (which focuses on internal research). AIDIF concentrates on commercial-stage digital health and AI-based externally developed solutions, with co-development and clinical workflow integration through MGB’s health system. Notable: DexCare, CARTA Healthcare.
Quick answers about which investors lead which stages, who’s most active, and how the digital health funding market actually works.
Join the curated platform 4,500+ clinicians, health system buyers, and investors use to discover digital health solutions. Build visibility with Digital.Health Growth Catalyst.
Learn more →Curated digital health news, deal flow, framework updates, and platform releases — relevant to investors, founders, and innovation leaders. Delivered to 30,000+ ecosystem leaders.
Subscribe free →Digital.Health Connect lets practices, pharmacies, and health systems feature a vetted subset of digital health solutions on a custom-branded platform. White-label or seamlessly integrated.
Request demo →Digital.Health curates 70 leading digital health investors across the U.S. and Europe in five stage categories: Seed & Pre-Seed (15 firms), Series A (15), Series B / C (13), Growth & Late Stage (14), and Strategic CVC & PE (13).
Curated by Daniel Kraft, MD, Stanford- and Harvard-trained physician-scientist and Founder of Digital.Health.
Common questions this index answers: Who are the most active digital health investors in 2024 and 2025? What should digital health founders look for in an investor? Which investors are best for AI in healthcare companies? Which investors are best for value-based care, payer/provider infrastructure, and health system deployment? Which VCs are dedicated digital health specialists vs generalists? What are the top European digital health investors? Which strategic corporate VCs (CVCs) are most active in digital health? Where should a digital health founder start their fundraise? Who leads late-stage and crossover digital health investing? How is digital health funding doing in 2025-2026?
Topics covered: digital health venture capital, healthcare AI investors, value-based care VCs, payer-tech investors, healthcare strategic CVCs, health system venture funds, healthcare crossover funds, healthcare private equity, late-stage digital health investing, growth equity healthcare, European digital health investors, U.S. digital health investors, healthcare workflow AI, FDA-regulated AI investors, founder fit by stage, fundraising strategy, the 2025-2026 digital health funding reset.